U.S. markets closed
  • S&P Futures

    3,840.25
    +31.00 (+0.81%)
     
  • Dow Futures

    31,128.00
    +216.00 (+0.70%)
     
  • Nasdaq Futures

    13,055.00
    +144.00 (+1.12%)
     
  • Russell 2000 Futures

    2,233.60
    +34.40 (+1.56%)
     
  • Crude Oil

    62.43
    +0.93 (+1.51%)
     
  • Gold

    1,746.60
    +17.80 (+1.03%)
     
  • Silver

    26.92
    +0.48 (+1.82%)
     
  • EUR/USD

    1.2080
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3967
    +0.0045 (+0.32%)
     
  • USD/JPY

    106.5100
    +0.0080 (+0.01%)
     
  • BTC-USD

    46,197.88
    +918.84 (+2.03%)
     
  • CMC Crypto 200

    922.59
    -10.54 (-1.13%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,588.47
    +622.46 (+2.15%)
     

Novocure to Host Virtual Research & Development Day

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research

Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to highlight progress across its clinical and product development pipelines and to introduce areas of internal and external focus in its translational research. The event will include presentations from various leaders of Novocure’s research and development teams as well as from key opinion leaders from across the global scientific community who are conducting research on Tumor Treating Fields.

The event will be webcast live and can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. The webcast will be available for replay for at least 14 days following the event. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer and glioblastoma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005387/en/

Contacts

Investors:
Gabrielle Fernandes
gfernandes@novocure.com
603-206-7047

Media:
Jaclyn Stahl
jstahl@novocure.com
212-767-7516